Patents by Inventor Aris N. Economides

Aris N. Economides has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7241739
    Abstract: Human Cerberus proteins and related nucleic acids are provided. Included are proteins comprising a human cerberus domain having specific activity, particularly the ability to antagonize a bone morphogenic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: July 10, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Eduardo A. Rojas, Aris N. Economides, Neil Stahl
  • Patent number: 7205148
    Abstract: Methods of creating mutations in genomic exons by inserting introns into the genomic exons via homologous recombination. Also, methods are provided for introducing modifications into genomic exons by inserting introns into the genomic exons via homologous recombination such that a mature mRNA transcript produced from a genomic region of the genome comprising the genomic exon does not contain the modification are provided. The methods provide for a rapid method for introducing mutations and/or modifications of any type into a mammalian cell genome.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: April 17, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, David M. Valenzuela, Samuel Davis, George Yancopoulos
  • Patent number: 6846908
    Abstract: DCR5, a protein related to DAN (Differential-screening-selected gene Aberrative in Neuroblastoma) and related nucleic acids are provided. Included are natural DCR5 homologs from several species and proteins comprising a DCR5 domain having specific activity, particularly the ability to antagonize a bone morphogenetic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: January 25, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Neil Stahl
  • Publication number: 20040132661
    Abstract: Methods of treating and/or inhibiting a bone morphogenetic protein (BMP)-related disorder or condition by administering a BMP antagonist to a subject suffering from a BMP-related disorder or condition such that the BMP-related disorder or condition is treated. The method is carried out with a human noggin or a human noggin deletion mutant.
    Type: Application
    Filed: December 12, 2003
    Publication date: July 8, 2004
    Inventors: Aris N. Economides, Neil Stahl, David M. Valenzuela, George D. Yancopoulos
  • Publication number: 20040106134
    Abstract: DCR5, a protein related to DAN (Differential-screening-selected gene Aberrative in Neuroblastoma) and related nucleic acids are provided. Included are natural DCR5 homologs from several species and proteins comprising a DCR5 domain having specific activity, particularly the ability to antagonize a bone morphogenetic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Application
    Filed: September 15, 2003
    Publication date: June 3, 2004
    Inventors: Aris N. Economides, Neil Stahl
  • Patent number: 6660499
    Abstract: DCR5, a protein related to DAN (Differential-screening-selected gene Aberrative in Neuroblastoma) and related nucleic acids are provided. Included are natural DCR5 homologs from several species and proteins comprising a DCR5 domain having specific activity, particularly the ability to antagonize a bone morphogenetic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: December 9, 2003
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Neil Stahl
  • Publication number: 20030199042
    Abstract: Human Cerberus proteins and related nucleic acids are provided. Included are proteins comprising a human cerberus domain having specific activity, particularly the ability to antagonize a bone morphogenic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Application
    Filed: June 19, 2003
    Publication date: October 23, 2003
    Inventors: David M. Valenzuela, Eduardo A. Rojas, Aris N. Economides, Neil Stahl
  • Patent number: 6610510
    Abstract: Human Cerberus proteins and related nucleic acids are provided. Included are proteins comprising a human cerberus domain having specific activity, particularly the ability to antagonize a bone morphogenic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: August 26, 2003
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Eduardo A. Rojas, Aris N. Economides, Neil Stahl
  • Patent number: 6586251
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: July 1, 2003
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Andrew J. Murphy, David M. Valenzuela, George D. Yancopoulos
  • Publication number: 20030084468
    Abstract: The present invention is a novel method of expressing transgenes in vivo by targeting protected transgene cassettes into predetermined loci, including ubiquitously expressed chromosomal loci, such that the activity of an exogenous promoter is maintained. The advantages of this method are that the expression pattern is determined primarily by the nature of the exogenous promoter and, therefore, is not subject to positional effects. The invention also encompasses the DNA targeting vectors, the targeted cells, as well as non-human organisms, especially mice, created from the targeted cells.
    Type: Application
    Filed: September 5, 2002
    Publication date: May 1, 2003
    Inventors: Aris N. Economides, Thomas M. DeChiara, Nicholas W. Gale, George D. Yancopoulos
  • Publication number: 20030003581
    Abstract: The present invention is a method of targeting promoter-less selection cassettes into transcriptionally active loci. In particular, the invention is a method for targeting promoter-less selection cassettes into transcriptionally active loci in stem cells or other eukaryotic cells with much greater efficiency than previously observed with other methods, thus reducing or eliminating the need to screen for targeted cells. The invention also encompasses the DNA targeting vectors, the targeted cells, as well as non-human organisms, especially mice, created from the targeted cells.
    Type: Application
    Filed: June 5, 2002
    Publication date: January 2, 2003
    Inventors: Aris N. Economides, Thomas M. DeChiara, George D. Yancopoulos
  • Publication number: 20020106628
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Application
    Filed: December 7, 2000
    Publication date: August 8, 2002
    Inventors: Aris N. Economides, Andrew J. Murphy, David M. Valenzuela, George D. Yancopoulos
  • Patent number: 5470952
    Abstract: Heterodimer proteins comprising a soluble .alpha. specificity determining cytokine receptor component and the extracellular domain of a .beta. receptor component function as CNTF and IL-6 antagonsists.
    Type: Grant
    Filed: October 20, 1993
    Date of Patent: November 28, 1995
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, Aris N. Economides, George D. Yancopoulos